Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients (TACAC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Baylor Breast Care Center
Sponsor:
Collaborator:
Baylor College of Medicine
Information provided by (Responsible Party):
Baylor Breast Care Center
ClinicalTrials.gov Identifier:
NCT00206518
First received: September 14, 2005
Last updated: November 18, 2014
Last verified: November 2014

September 14, 2005
November 18, 2014
September 2004
September 2015   (final data collection date for primary outcome measure)
assess clinical tumor response to neoadjuvant chemotherapy (Taxotere and AC) and to validate that clinical response strongly correlates with prospectively-determined regimen-specific gene expression profiles of sensitivity and resistance [ Time Frame: 10 years ] [ Designated as safety issue: No ]
assess clinical tumor response to neoadjuvant chemotherapy (Taxotere and AC) and to validate that clinical response strongly correlates with prospectively-determined regimen-specific gene expression profiles of sensitivity and resistance.
Complete list of historical versions of study NCT00206518 on ClinicalTrials.gov Archive Site
determine time to tumor progression; median overall survival; and document toxicities associated with the chemotherapy regimens [ Time Frame: 10 years ] [ Designated as safety issue: No ]
determine time to tumor progression; median overall survival; and document toxicities associated with the chemotherapy regimens.
Not Provided
Not Provided
 
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
A Randomized Multicenter Trial of Neoadjuvant Taxotere (T) and Adriamycin/Cytoxan (Ac): A Validation

The purpose of this study is to learn if the biomarker information obtained (learned or received) from the earlier studies can tell us whether or not Taxotere and/or Adriamycin/Cytoxan can cause tumors to become smaller.

Large clinical trials have confirmed the value of systemic adjuvant therapy in decreasing the risk of recurrence and death in patients with early breast cancer. However, the need to identify breast cancer patients who will benefit from adjuvant therapy, while sparing others from the side effects of futile treatment, is spurring research into predictive markers of chemotherapy sensitivity and resistance. In the adjuvant setting, extremely large trials and long follow-up would be required to prospectively validate the predictive value of biomarkers of chemotherapy sensitivity or resistance. In part this is because response is not directly observable. Preoperative chemotherapy for large tumors (>3cm) or inoperable breast cancer is well established and is the standard of care for locally advanced breast cancer. Data from large series of patients have demonstrated that preoperative (neoadjuvant) chemotherapy leads to significant reduction of tumor size (downstaging) and improves both the rate and the cosmetic results of breast- conserving surgery. The degree of response to neoadjuvant therapy has been shown to predict improved overall survival. This is therefore an attractive setting to study predictors of response because tissue is accessible from pre- therapeutic biopsies and tumor response is directly observable.

In an early proof-of-principle pilot study of single agent neoadjuvant docetaxol, we identified a predictive gene expression pattern, and, using leave-one-cross validation, a method of internal validation, we demonstrated that the pattern was likely to accurately discriminate between responders and non-responders (Chang, J.C., et al., Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet, 2003. 362(9381): p. 362-9). A similar pilot study of neoadjuvant AC undertaken by a collaborator in the UK suggests that different profiles will be predictive for AC response.

In order to definitively determine predictive patterns for both regimens (T and AC) using improved technology for RNA preparation and a larger, more comprehensive gene expression array, we undertook a randomized Phase II trial of these two widely used regimens (Protocol H-11624 - A RANDOMIZED MULTICENTER TRIAL OF NEOADJUVANT TAXOTERE AND ADRIAMYCIN/CYTOXAN (AC): A BIOLOGIC CORRELATIVE STUDY). The trial is nearing completion, having recruited more than 90 patients out of an expected 120 patients. To date, the risks associated with this study have been modest, and there have been no unexpected adverse events. The laboratory work is well underway and gives every indication that clinically useful classifiers to predict treatment efficacy will result.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Breast Cancer
  • Drug: Taxotere
    Taxotere
    Other Name: docetaxel
  • Drug: Adriamycin/Cytoxan
    Adriamycin/Cytoxan
    Other Name: doxorubicin
  • Drug: docetaxol
    Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery.
    Other Name: docetaxol, taxotere
  • Drug: doxorubicin
    AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.
    Other Name: AC, ADRIAMYCIN/CYTOXAN
  • Active Comparator: A
    Chemotherapy In Arm A, patients will receive single agent Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. This will be followed by standard adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles. For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. This is done in order to minimize Adriamycin-induced cardiotoxicity.
    Interventions:
    • Drug: Taxotere
    • Drug: docetaxol
  • Active Comparator: B
    In Arm B, patients will receive AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery. For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. This will be followed by 4 cycles of single agent Taxotere (100 mg/m2) every 3 weeks.
    Interventions:
    • Drug: Adriamycin/Cytoxan
    • Drug: doxorubicin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
153
September 2016
September 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. All patients must be female.
  2. Signed informed consent.
  3. Primary breast cancers must be of clinical and/or radiologic size >3 cm, and deemed surgically operable.
  4. Negative serum pregnancy test (bHCG) within 7 days of starting study, if of child-bearing potential.
  5. Adequate bone marrow function:

    • Hematocrit of greater than 30%,
    • total neutrophil count must be >1.5 x 10^9/L and
    • platelets of > 100 x 10^9/L prior to the start of any cycle.
  6. Renal function tests:

    • creatinine within 1.5 times of the institution's upper limit of normal (ULN).
  7. Liver function tests:

    • Total serum bilirubin within ULN, and
    • liver transaminases within 2.5 times ULN, and
    • alkaline phosphatase within 5 times ULN.
  8. Electrocardiogram showing no acute ischemic changes.
  9. Performance status (World Health Organization [WHO] scale) <2.
  10. Age > 18 years.
  11. Patients older than 70 years of age should have left ventricular ejection fraction within ULN by multigated acquisition scan (MUGA) or 2D echocardiogram.

Exclusion Criteria:

  1. Patients with metastatic breast cancer.
  2. Pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential.
  3. Women who are lactating or breastfeeding.
  4. Severe underlying chronic illness or disease.
  5. Peripheral neuropathy - grade 2 or greater.
  6. Patients on other investigational drugs while on study will be excluded.
  7. Severe or uncontrolled hypertension, history of congestive heart failure, acute myocardial infarction, or severe coronary arterial disease.
  8. Prior taxane or anthracycline chemotherapy for malignancy.
  9. Patients with a history of severe hypersensitivity reaction to Taxotere or other drugs formulated with polysorbate 80.
  10. No previous or current malignancies at other sites within the last 5 years, with exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.
Female
18 Years and older
No
Contact: Kristen Otte, BS, CRC 713-798-1999 kristen.otte@bcm.edu
Contact: Brenda Reusser, BA 713-798-1929 breusser@bcm.edu
United States
 
NCT00206518
H 16039
Yes
Baylor Breast Care Center
Baylor Breast Care Center
Baylor College of Medicine
Principal Investigator: Mothaffar Rimawi, MD Baylor Breast Center
Baylor Breast Care Center
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP